Mediwound (MDWD) Received its Third Buy in a Row

After Cowen & Co. and BTIG gave Mediwound (NASDAQ: MDWD) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Kevin DeGeeter maintained a Buy rating on Mediwound today and set a price target of $7.00. The company’s shares closed last Tuesday at $4.24.

According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 38.8% and a 44.7% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Sensei Biotherapeutics, and Cellectar Biosciences.

Mediwound has an analyst consensus of Strong Buy, with a price target consensus of $6.25.

See today’s analyst top recommended stocks >>

Based on Mediwound’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.85 million and GAAP net loss of $2.85 million. In comparison, last year the company earned revenue of $4.44 million and had a GAAP net loss of $2.46 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.